Biotest Aktiengesellschaft (BIESF)
USD 32.0
(0.0%)
USD 32.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 280.3 Million EUR | 124.42% |
| 2022 | 124.9 Million EUR | 54.77% |
| 2021 | 80.7 Million EUR | -37.97% |
| 2020 | 130.1 Million EUR | 1.01% |
| 2019 | 128.8 Million EUR | -4.45% |
| 2018 | 134.8 Million EUR | 9.15% |
| 2017 | 123.5 Million EUR | -39.31% |
| 2016 | 203.5 Million EUR | 44.02% |
| 2015 | 141.3 Million EUR | -37.06% |
| 2014 | 224.5 Million EUR | 8.14% |
| 2013 | 207.6 Million EUR | 12.42% |
| 2012 | 184.66 Million EUR | 10.08% |
| 2011 | 167.76 Million EUR | 1.99% |
| 2010 | 164.48 Million EUR | -22.53% |
| 2009 | 212.32 Million EUR | -3.11% |
| 2008 | 219.13 Million EUR | -54.37% |
| 2007 | 480.25 Million EUR | 243.09% |
| 2006 | 139.98 Million EUR | 11.0% |
| 2005 | 126.1 Million EUR | 21.57% |
| 2004 | 103.72 Million EUR | 6.39% |
| 2003 | 97.49 Million EUR | -15.8% |
| 2002 | 115.78 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 51.1 Million EUR | -43.6% |
| 2024 Q1 | 90.6 Million EUR | 31.11% |
| 2023 Q3 | 166.4 Million EUR | 248.85% |
| 2023 Q4 | 69.1 Million EUR | -58.47% |
| 2023 Q2 | 47.7 Million EUR | 93.12% |
| 2023 Q1 | 24.7 Million EUR | -44.12% |
| 2023 FY | 280.3 Million EUR | 124.42% |
| 2022 Q3 | 23.6 Million EUR | -23.38% |
| 2022 Q4 | 44.2 Million EUR | 87.29% |
| 2022 FY | 124.9 Million EUR | 54.77% |
| 2022 Q1 | 26.2 Million EUR | 2481.82% |
| 2022 Q2 | 30.8 Million EUR | 17.56% |
| 2021 Q4 | -1.1 Million EUR | -104.26% |
| 2021 Q1 | 23 Million EUR | -39.15% |
| 2021 Q2 | 33 Million EUR | 43.48% |
| 2021 Q3 | 25.8 Million EUR | -21.82% |
| 2021 FY | 80.7 Million EUR | -37.97% |
| 2020 FY | 130.1 Million EUR | 1.01% |
| 2020 Q1 | 28.5 Million EUR | -36.1% |
| 2020 Q2 | 37.6 Million EUR | 31.93% |
| 2020 Q3 | 26.2 Million EUR | -30.32% |
| 2020 Q4 | 37.8 Million EUR | 44.27% |
| 2019 FY | 128.8 Million EUR | -4.45% |
| 2019 Q4 | 44.6 Million EUR | 52.22% |
| 2019 Q3 | 29.3 Million EUR | -17.23% |
| 2019 Q2 | 35.4 Million EUR | 81.54% |
| 2019 Q1 | 19.5 Million EUR | -47.44% |
| 2018 FY | 134.8 Million EUR | 9.15% |
| 2018 Q4 | 37.1 Million EUR | 9.76% |
| 2018 Q3 | 33.8 Million EUR | 0.3% |
| 2018 Q2 | 33.7 Million EUR | 11.59% |
| 2018 Q1 | 30.2 Million EUR | 41.78% |
| 2017 FY | 123.5 Million EUR | -39.31% |
| 2017 Q4 | 21.3 Million EUR | -48.8% |
| 2017 Q3 | 41.6 Million EUR | -14.75% |
| 2017 Q2 | 48.8 Million EUR | 313.56% |
| 2017 Q1 | 11.8 Million EUR | -83.12% |
| 2016 Q2 | 48.4 Million EUR | 5.22% |
| 2016 Q4 | 69.9 Million EUR | 78.32% |
| 2016 Q3 | 39.2 Million EUR | -19.01% |
| 2016 FY | 203.5 Million EUR | 44.02% |
| 2016 Q1 | 46 Million EUR | -32.15% |
| 2015 Q3 | -19.2 Million EUR | -139.75% |
| 2015 Q2 | 48.3 Million EUR | 8.78% |
| 2015 Q1 | 44.4 Million EUR | -26.0% |
| 2015 FY | 141.3 Million EUR | -37.06% |
| 2015 Q4 | 67.8 Million EUR | 453.13% |
| 2014 FY | 224.5 Million EUR | 8.14% |
| 2014 Q3 | 54.5 Million EUR | -7.31% |
| 2014 Q4 | 60 Million EUR | 10.09% |
| 2014 Q2 | 58.8 Million EUR | 14.84% |
| 2014 Q1 | 51.2 Million EUR | -4.3% |
| 2013 Q4 | 53.5 Million EUR | 3.88% |
| 2013 FY | 207.6 Million EUR | 12.42% |
| 2013 Q2 | 53.2 Million EUR | 7.69% |
| 2013 Q1 | 49.4 Million EUR | -0.53% |
| 2013 Q3 | 51.5 Million EUR | -3.2% |
| 2012 FY | 184.66 Million EUR | 10.08% |
| 2012 Q2 | 46 Million EUR | -2.95% |
| 2012 Q3 | 41.6 Million EUR | -9.57% |
| 2012 Q4 | 49.66 Million EUR | 19.38% |
| 2012 Q1 | 47.4 Million EUR | 4.5% |
| 2011 Q2 | 42.8 Million EUR | 11.17% |
| 2011 Q4 | 45.36 Million EUR | 10.37% |
| 2011 Q3 | 41.1 Million EUR | -3.97% |
| 2011 FY | 167.76 Million EUR | 1.99% |
| 2011 Q1 | 38.5 Million EUR | 66.07% |
| 2010 Q1 | 52.2 Million EUR | -1.92% |
| 2010 Q4 | 23.18 Million EUR | -46.34% |
| 2010 Q2 | 45.9 Million EUR | -12.07% |
| 2010 FY | 164.48 Million EUR | -22.53% |
| 2010 Q3 | 43.2 Million EUR | -5.88% |
| 2009 FY | 212.32 Million EUR | -3.11% |
| 2009 Q4 | 53.22 Million EUR | 4.97% |
| 2009 Q3 | 50.7 Million EUR | -7.14% |
| 2009 Q2 | 54.6 Million EUR | 1.49% |
| 2009 Q1 | 53.8 Million EUR | 0.0% |
| 2008 FY | 219.13 Million EUR | -54.37% |
| 2007 FY | 480.25 Million EUR | 243.09% |
| 2006 FY | 139.98 Million EUR | 11.0% |
| 2005 FY | 126.1 Million EUR | 21.57% |
| 2004 FY | 103.72 Million EUR | 6.39% |
| 2003 FY | 97.49 Million EUR | -15.8% |
| 2002 FY | 115.78 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bioxytran, Inc. | -8285.00 USD | 3383322.692% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -1768.791% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -2761.956% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -426354.479% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -2294.499% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | -135.333% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 820890.63% |
| Marizyme, Inc. | 457.7 Thousand USD | -61140.72% |
| Genus plc | 178.7 Million USD | -56.855% |
| Pharming Group N.V. | 220.1 Million USD | -27.349% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -450354.794% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -68238.352% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 2548281.818% |
| ContraFect Corporation | -154 Thousand USD | 182112.987% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -365059.391% |
| IMV Inc. | -962.29 Thousand USD | 29228.191% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 72435.297% |
| ONE Bio Corp. | 20.12 Million USD | -1292.765% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -596.138% |
| Mesoblast Limited | -35.16 Million USD | 897.031% |
| MultiCell Technologies, Inc. | 49.32 USD | -568329178.183% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -892.037% |
| Genscript Biotech Corporation | 409.55 Million USD | 31.56% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -9036005.738% |
| Biomind Labs Inc. | -15.42 Thousand USD | 1817397.718% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 24653.861% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -400328.571% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 225691.746% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 5660439.257% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 560700.0% |
| Arch Therapeutics, Inc. | -2439.00 USD | 11492514.924% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -199401.779% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -573110.634% |
| Q BioMed Inc. | -8988.00 USD | 3118702.581% |
| GB Sciences, Inc. | -624.00 USD | 44919971.795% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 325924.15% |
| CSL Limited | 7.56 Billion USD | 96.293% |
| Agentix Corp. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -531.907% |
| Enzolytics Inc. | 30.7 Thousand USD | -912691.455% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -58001.332% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 287542.957% |
| argenx SE | 1.1 Billion USD | 74.713% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 1186.518% |
| HST Global, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 134759715.385% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 54579.019% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 3165185.818% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -45301.241% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 334391.405% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -28270.991% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -2816.45% |
| Kadimastem Ltd | -630.13 Thousand USD | 44582.32% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | -1717.198% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 2368498.817% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 580924.302% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -158656.23% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -158656.23% |
| Affymax, Inc. | 1.35 Million USD | -20553.682% |
| Mobile Lads Corp. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -5982.899% |
| CytoDyn Inc. | -29 Thousand USD | 966651.724% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -62182.937% |
| SYBLEU INC | 11.69 Thousand USD | -2396445.828% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 87828.907% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 75247.453% |
| Neutra Corp. | 14.33 Thousand USD | -1955254.029% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 341929.268% |
| PureTech Health plc | -1.6 Million USD | 17585.964% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 28095.398% |
| IXICO plc | 3.27 Million USD | -8471.865% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 40489.049% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 15750.475% |
| CSL Limited | 7.7 Billion USD | 96.362% |
| Cellectis S.A. | 18 Thousand USD | -1557122.222% |